RT Journal Article
T1 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines
A1 Seoane Ruzo, Samuel
A1 Álvarez Bermúdez, María José
A1 Sendón Lago, Juan José
A1 Martínez Ordóñez, Anxo
A1 Abdul-Hadi, Soraya
A1 Maestro Saavedra, Miguel Anxo
A1 Mouriño Mosquera, Antonio
A1 Pérez Fernández, Román
K1 1a,25-dihydroxyvitamin D3
K1 26,26,26,27,27,27-hexadeuterated 1a
K1 25-dihydroxyvitamin D3
K1 Vitamin D
K1 Deuterated vitamin D
K1 Chemotheraphy
K1 Breast cancer
AB It has been demonstrated that 1,25-dihydroxyvitamin D3 (1,25D) and some of its analogues have antitumor activity. 1,25D labeled with deuterium (26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin D3, or 1,25D-d6) is commonly used as internal standard for 1,25D liquid chromatography-mass spectrometry (LC-MS) quantification. In the present study using human breast cancer cell lines, the biological activity of 1,25D-d6 administered alone and in combination with two commonly used antineoplastic agents, 5-fluorouracil and etoposide, was evaluated. Using an MTT assay, flow cytometry, and western blots, our data demonstrated that 1,25D-d6 has effects similar to the natural hormone on cell proliferation, cell cycle, and apoptosis. Furthermore, the combination of 1,25D-d6 and etoposide enhances the antitumoral effects of both compounds. Interestingly, the antitumoral effect is higher in the more aggressive MDA-MB-231 breast cancer cell line. Our data indicate that 1,25D-d6 administered alone or in combination with chemotherapy could be a good experimental method for accurately quantifying active 1,25D levels in cultures or in biological fluids, on both in vitro breast cancer cell lines and in vivo animal experimental models
PB MDPI
YR 2013
FD 2013
LK http://hdl.handle.net/10347/23007
UL http://hdl.handle.net/10347/23007
LA eng
NO Seoane, S.; Bermudez, M.A.; Sendon-Lago, J.; Martinez-Ordoñez, A.; Abdul-Hadi, S.; Maestro, M.; Mouriño, A.; Perez-Fernandez, R. 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers 2014, 6, 67-78
NO Samuel Seoane is a fellow from Fundación Científica de la Asociación Española Contra el Cáncer. This study was supported by a grant to R.P.-F. from Ministerio de Economía y Competividad (SAF2012-38240), and to A.M. from Ministerio de Educación e Innovación (MEI) (SAF2010–15291), and Xunta de Galicia (CN2012/074, INCITE08PXIB209130PR)
DS Minerva
RD 28 abr 2026